UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004385
Receipt number R000005217
Scientific Title Prognostic Siginificance of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Limited Stage Small Cell Lung Cancer
Date of disclosure of the study information 2010/10/14
Last modified on 2011/11/15 14:55:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prognostic Siginificance of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Limited Stage Small Cell Lung Cancer

Acronym

Prognostic Siginificance of FDG-PET in Patients with Limited Stage Small Cell Lung Cancer

Scientific Title

Prognostic Siginificance of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Limited Stage Small Cell Lung Cancer

Scientific Title:Acronym

Prognostic Siginificance of FDG-PET in Patients with Limited Stage Small Cell Lung Cancer

Region

Japan


Condition

Condition

Limited Stage Small Cell Lung Cancer

Classification by specialty

Medicine in general Pneumology Hematology and clinical oncology
Radiology Laboratory medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the prognostic siginificance of (18)F-fluorodeoxyglucose positron emission tomography in patients with limited-stage small-cell lung cancer who received 4 cycles of etoposide and cisplatin plus early concurrent accelerated hyperfractionated thoracic irradiation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Overall survival

Key secondary outcomes

Progression free survival
Response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

CDDP+VP-16 4 cycles
CDDP 80mg/m2 day1, VP-16 100mg/m2 day1-3
early concurrent twice-daily RT 1.5Gy 30fraction

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

74 years-old >=

Gender

Male and Female

Key inclusion criteria

1) cytologically, histologically proven small-cell lung cancer
2) limited disease except c-stage I
3) age 20-74 years old
4) performance status of 0-1
5) measurable disease
6) no prior treatment for small-cell lung cancer
7) no history of chemotherapy
8) adequate organ functions
9) written informed consent

Key exclusion criteria

1) pericardial effusion
2) active concomitant malignancy
3) pregnant or lactating women
4) interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea, intestinal obstruction or paralysis, uncontrolled heart disease or a history of myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus, active infection, psychological disease deemed unacceptable for inclusion to the study, long-term steroid treatment.

Target sample size

38


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yukito Ichinose

Organization

National Kyushu Cancer Center

Division name

Department of Thoracic Oncology

Zip code


Address

Fukuoka

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Noriyuki Ebi

Organization

Iizuka Hospital

Division name

Department of respiratory medicine

Zip code


Address


TEL

0948-22-3800

Homepage URL


Email



Sponsor or person

Institute

Lung Oncology Group in Kyushu, Japan (LOGIK)

Institute

Department

Personal name



Funding Source

Organization

Clinical Research Support Center kyushu

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 10 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 09 Month 04 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 10 Month 14 Day

Last modified on

2011 Year 11 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005217


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name